Q-omics provides the consensus-scored TRAJ22 profile across patient tissues and cancer cell-line models. TRAJ22 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in GBM. Among the 18 cancer types available for tumor–normal comparison, TRAJ22 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, TRAJ22 RNA expression shows 11,817 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight GBM, BRCA, and LSCC as cancer lineages where TRAJ22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ22 survival associations across molecular data types. TRAJ22 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ22 RNA expression–survival associations across cancer types. High TRAJ22 expression shows unfavorable associations in GBM, BLCA, HNSC and READ, but favorable associations in DLBC and SKCM. The GBM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify GBM as the clearest survival context for TRAJ22 RNA expression.
This table summarizes TRAJ22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ22 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUSC and KIRC. The BRCA box plot shows higher TRAJ22 RNA expression in tumor versus normal tissue (log2 FC = +0.265, t-test p = .019).
This table shows molecular features associated with TRAJ22 in patient tissues and cancer cell lines. In patient samples, TRAJ22 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
